FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitis
The monoclonal antibody treatment is for patients ages 12 years and older
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
The monoclonal antibody treatment is for patients ages 12 years and older
Only registered members have full access to PracticeUpdate content.